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Several studies describe the results of bronchoplastic
operations by using univariate analyses in most cases.1-3
Multivariable analyses have been rarely performed.4,5
We carried out a multivariable analysis to determine
putative prognostic factors for survival.
Patients and methods
Patients. Between January 1, 1991, and December 31,
1997, 144 bronchoplastic procedures were performed at the
two main centers of thoracic surgery in Vienna (at the
Department of Cardiothoracic Surgery, University of Vienna,
and the Department of Thoracic Surgery, Center of
Pulmology). The patients consisted of 110 (76%) men and 34
(24%) women, with a mean age of 59.8 ± 10.5 years (range,
24-79 years). Twenty-one (15%) patients were at least 70
years old, and 43 (30%) had a respiratory risk (ie, chronic
obstructive pulmonary disease defined as forced expiratory
volume in 1 second [FEV1] of < 60% of predicted value). For
all patients, the mean FEV1 was 73.2% ± 15.7%. Fifty-five
B ronchoplastic procedures for malignant and nonma-lignant disease are widely accepted procedures.
Objectives: We sought to analyze the experience with bronchoplastic proce-
dures over a 7-year period and to determine putative prognostic factors for
survival.
Methods: From 1991 to 1997, 144 bronchoplastic procedures were per-
formed for non–small cell lung cancer (n = 123), small cell lung cancer (n =
5), carcinoid tumor (n = 10), and metastases of extrathoracic malignant
tumors (n = 6). There were 111 sleeve lobectomies, 17 bilobectomies, 4
lobectomies with carinal resection, 8 sleeve pneumonectomies, and 4 bron-
chotomies without parenchymal resection. Multivariable analysis included
risk factors, such as age, sex, type of bronchoplastic procedure (bronchoto-
my, lobectomy, bilobectomy, or pneumonectomy), additional angioplasty,
TNM staging, histology, radicality of resection, respiratory risk (forced expi-
ratory volume in 1 second, percent predicted < 60), cardiovascular risk, and
adjuvant therapy.
Results: Overall 1- and 3-year survival was 72% and 52%, respectively. The
overall 30-day mortality was 8.3% (5.4% for single sleeve lobectomies).
Multivariable analysis demonstrated 4 risk factors for survival. High tumor
stage, type of bronchoplastic procedure, impaired lung function, and pres-
ence of cardiovascular risk were associated with a poor outcome. Univariate
analysis showed reduced survival in patients with sleeve pneumonectomies
(1-year survival, 25%).
Conclusions: Bronchoplastic procedures for central tumors and sleeve pneu-
monectomies are associated with poor survival. Careful selection of these
patients, as well as of patients with impaired lung function and cardiovascu-
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(38%) patients had a cardiovascular risk factor (ie, cardiac
insufficiency or arrhythmia, coronary disease, myocardial
infarction, chronic cerebral occlusive disease, or stroke).
Sixty-seven (47%) events (ie, deaths) occurred, and 77 (53%)
patients were censored.
Preoperative staging included chest radiography, computed
tomography of the chest and upper abdomen, bronchoscopy,
and upper abdominal ultrasonography; computed tomogra-
phy of the cerebrum and bone scintigraphy were done in
selected cases.
Operative procedure. Bronchoplastic procedures consist-
ed of 111 lobectomies (right upper lobe, n = 69; right middle
lobe, n = 1; right lower lobe, n = 4; left upper lobe, n = 26;
and left lower lobe, n = 11), 17 bilobectomies (upper, n = 12;
lower, n = 5), 4 right upper lobectomies with carinal resec-
tion, 8 sleeve pneumonectomies, and 4 bronchoplastic proce-
dures without parenchymal resection (wedge resection of the
apical segmental bronchus of the right lower lobe, resection
of the right upper lobe bronchus, resection of the stump of the
left upper lobe bronchus, and resection of the left upper lobe
carina and the proximal segment of the lower lobe bronchus).
The procedures were performed on the right side in 103
(72%) patients and on the left side in 41 (28%) patients.
Resection of the right upper lobe was the most common pro-
cedure and was performed in 72 (63%) of 115 resections of
single lobes.
Type of resection. In 116 (81%) patients a full sleeve
resection was performed, and in 28 (19%) patients an incom-
plete sleeve or wedge bronchoplasty was performed.
Additional angioplasty was performed in 23 (16%)
patients, including angioplasty of the pulmonary artery in
19 patients (7 circular resections with end-to-end anasto-
moses and 12 tangential resections), 3 angioplasties of the
superior caval vein (1 tube graft replacement and 2 tangen-
tial resections), and 1 local resection with patch angioplas-
ty of the aorta. Five (3.5%) patients had en bloc resection
of the thoracic wall and sleeve lobectomy, and 8 (5.6%)
patients had an additional wedge resection of the remaining
lobe. For extended resections, cardiopulmonary bypass was
used in 3 cases (right-sided pneumonectomy with resection
of the carina and superior caval vein, left-sided pneu-
monectomy with wedge resection of the trachea and aorta,
or left-sided pneumonectomy with resection of the carina
and the right main bronchus).
Histology. Indications for operation were non–small cell
lung cancer (NSCLC; n = 123), small cell lung cancer (n = 5),
carcinoid tumor (n = 10), and metastases of extrathoracic
malignant tumors (n = 6; hypernephroid carcinoma in 4 cases
and breast and endometrial carcinoma in 1 case each).
Radicality of resection. Resections with completely
tumor-free bronchial resection margins were defined as com-
plete resections and were achieved in 130 (90.3%) patients.
In 14 (9.7%) patients incomplete resections with histologi-
cally residual tumor were performed. No patient had visible
residual tumor at the bronchial resection margins.
Staging. The TNM classification is given in Table I in
accordance with the most recent International Union Against
Cancer (UICC) classification.6 Five patients with stage IV dis-
ease had cerebral metastases that had been resected before the
lung operation, and 2 patients had single metastases in anoth-
er lobe. One male patient had carcinoma in situ (stage 0).
According to the type of operation, the general characteris-
tics of patients are listed in Table II. Follow-up of patients
was completed in February 1999.
Statistical methods. To explore the influence of 10 risk
factors on survival, we estimated a multivariable Cox regres-
sion model by using a stepwise variable selection procedure
with the SAS procedure PHREG (SAS Institute, Inc, Cary,
NC).7 The risk factors, as well as their mathematical terms
and coding, are listed in Table III. One of the factors investi-
gated is tumor stage. No TNM stage is assigned to 6 patients
with metastases of extrathoracic malignant disease; they are
included in the multivariable analysis by means of informa-
tive imputation. These patients are assigned a TNM stage
value of 6, and this group is identified by its own dichoto-
mous variable (Table III).
The probabilities for inclusion and exclusion of risk factors
are chosen to equal .05. The Wald χ2 test was used to test
individual regression parameters. Ninety-five percent confi-
dence intervals (CIs) for relative risk are given as appropriate.
In addition, univariable analyses were performed to obtain
survival curves according to the Kaplan-Meier estimate.8 The
log-rank test was used to assess the difference in survival
curves (SAS LIFETEST). For rejection of a null hypothesis,
a P value less than .05 is considered statistically significant.
Baseline values are given as means ± SD.
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Table I.  Stage of tumor in patients undergoing bron-
choplastic resection (n = 137)


















T3 N0 M1 1
T1 N1 M1 1
T2 N1 M1 4
T2 N2 M1 1
Six patients with metastases of extrathoracic malignant tumors and 1 patient
with Tis N0 M0 are not listed.
Results
Univariable survival analysis. Overall median
follow-up for all patients was 21 months (1 day–83
months). Median follow-up for patients alive is 27.5
months (0.5-83 months). Seventeen (12%) patients
were followed up for less than 14 months. Median
survival of the patients who died was 7.9 months (1
day–63 months). Overall survival is given in Fig 1.
Factors affecting survival. According to stage, 1-
year survival was 86% in stage I (CI, 75%-96%), 77%
in stage II (CI, 64%-89%), 68% in stage IIIA (CI, 52%-
84%), 30% in stage IIIB (CI, 2%-58%), and 29% in
stage IV (CI, 0-62%). Three-year survival was 70%
(CI, 54%-85%), 56% (CI, 39%-73%), and 42% (CI,
24%-60%) for stage I, II, and IIIA disease, respective-
ly (P = .003 for all stages). There was a clear difference
between stage I, II, and IIIA disease and stage IIIB and
IV disease (P = .0002). Differences between stage I, II,
and IIIA disease were not significant (P = .29), and
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Table II. Characteristics of patients by bronchoplastic procedure (n = 144)
Surgical procedure Bronchotomy Lobectomy Bilobectomy Pneumonectomy
No. of patients 4 115 17 8
Age, y (mean ± SD) 47 ± 21 60 ± 10 63 ± 8 56 ± 11
Sex, M (%) 2   (50) 84 (73) 17 (100) 7  (88)
Angioplasty, yes (%) 0 18 (16) 2   (12) 3  (38)
TNM stage (%)
I 3 (100) 39 (36) 2   (12) 0
II 0 33 (31) 10   (59) 1   (13)
IIIA 0 26 (24) 4   (23) 2   (25)
IIIB 0 5   (5) 0 5  (63)
IV 0 6   (6) 1    (6) 0
Histology (%)
NSCLC 1   (25) 97 (84) 17 (100) 8 (100)
SCLC 0 5   (4) 0 0
Carcinoid 2   (50) 8   (7) 0 0
Metastasis 1   (25) 5   (4) 0 0
Complete resection (%) 4 (100) 106 (92) 16   (94) 4   (50)
Respiratory risk (%) 0 34 (30) 6   (35) 3   (38)
Cardiovascular risk (%) 0 45 (39) 8   (47) 2   (25)
Adjuvant therapy (%)
None 4 (100) 62 (54) 12   (71) 3   (38)
Chemotherapy 0 28 (24) 2   (12) 0
Radiotherapy 0 15 (13) 3   (18) 4   (50)
Both 0 10   (9) 0 1   (13)
SCLC, Small cell lung cancer.
Table III. Risk factors (covariables) for survival investigated in the multivariable analysis of bronchoplastic 
procedures (1991-1997; n = 144)
Risk factor Kind of variable Terms Code Description
Age (at time of operation) Numerical Linear Number Years
Sex Class — 0,1 Male, female
Type of surgical procedure Numerical Linear + quadratic 0,1,2,3 Bronchotomy, lobectomy, bilobectomy, pneumonectomy
Angioplastic procedure Class — 0,1 Yes, no
TNM stage Numerical Linear + quadratic + cubic 0,1,2,3,4,5,6 0, I, II, IIIA, IIIB, IV, missing*
Histology Class — 1,2,3,4 NSCLC, SCLC, carcinoid, metastases*
Radicality of resection Class — 0,1 Complete, incomplete
Respiratory risk Class — 0,1 Yes, no
Cardiovascular risk Class — 0,1 Yes, no
Adjuvant therapy† Class — 0,1,2,3 Radiotherapy, chemotherapy, both, none
*Metastases of extrathoracic malignant tumors.
†Including 5 cases of neoadjuvant therapy.
there was also no difference between stage IIIB and IV
disease (P = .36). The survival curve for stage IV dis-
ease lies above the curve for stage IIIB disease. In stage
IIIB disease 2 patients are alive 2.8 and 5.1 years post-
operatively; in stage IV disease 2 patients are alive at
1.1 and 2.6 years, respectively (Fig 2).
Survival between T stages differed significantly (Fig
3). For T1 to T4, 1-year survival was 95% (CI, 88%-
100%), 69% (CI, 58%-79%), 54% (CI, 27%-81%), and
30% (CI, 2%-58%), respectively. For T1 to T3, 3-year
survival was 72% (CI, 54%-91%), 47% (CI, 34%-
61%), and 34% (CI, 5%-62%), respectively.
Fig 4 demonstrates survival by operative procedure.
Bilobectomies tended to have poorer results than lobec-
tomies within 3 years postoperatively; sleeve pneu-
monectomies had a 1-year survival of 25% (CI, 0%-
55%). Regarding surgical techniques, the 1-year
survival of patients with wedge bronchoplasties, full
sleeve resections, and sleeve pneumonectomies was
82%, 73%, and 25%, and 3-year survival was 66%,
50%, and 13%, respectively (P = .01).
Patients with poor lung function survived for signifi-
cantly shorter periods than patients without respiratory
risk (Fig 5), as did patients with a cardiovascular risk
factor (Fig 6).
The remaining factors tended to exert some influence
on survival but exhibited no statistical significance.
Survival according to nodal status demonstrated 1-year
survivals of 80% for N0 (CI, 68%-91%), 71% for N1
(CI, 59%-83%), and 59% for N2 (CI, 41%-77%) and 3-
year survivals of 63% (CI, 48%-78%), 53% (CI, 38%-
68%), and 36% (CI, 18%-54%), respectively (P = .2).
Concerning histology, patients with carcinoids seemed
to have a better prognosis than patients with NSCLC 
(P = .2). Highly differentiated tumors had increased
survival in contrast to undifferentiated tumors (P = .1).
Additional angioplasty tended to influence survival
adversely (P = .2). Adjuvant therapy also had no sig-
nificant effect (P = .2). No influence was found for the
variables of sex, surgeon, hospital, and radicality of
resection.
Postoperative mortality and complications.
Overall 30-day mortality was 8.3% (12/144). The caus-
es of death are listed in Table IV. Five patients died
within 1 week, resulting in a 7-day mortality of 3.5%
(5/144). For single sleeve lobectomies, 30-day mortal-
ity was 5.4% (6/136). Including bilobectomies, 30-day
mortality was 6.2% (8/128).
Other fatal complications within 3 months and
beyond 30 days are shown in Table V. Anastomotic
dehiscence occurred in 3 (2.8%) patients who died after
completion pneumonectomy (1 patient had  empyema),
1 further patient had partial anastomotic necrosis but
died of massive pulmonary embolism, and 1 patient
with partial necrosis was managed conservatively by
means of tube drainage. Thus, the overall anastomotic
complication rate was 3.5% (5/144).
Major and minor morbidity. Nonfatal complications
were managed conservatively in most cases. Patients
with hemothorax required rethoracotomy, and the
patient with adhesion ileus underwent laparotomy on
the second postoperative day (Table V).
Recurrence and metastases. In 52 (36%) of 144
patients, local recurrence or distant metastases
occurred. Thirty-seven patients died with disease,
accounting for 56% (37/66) of all deaths.
Multivariable analysis. The model selection proce-
dure includes the variables of TNM stage, type of bron-
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Fig 1. Overall survival after bronchoplastic operation (1991-
1997; n = 144). Dashed lines and values in brackets present
the 95% CIs for the 1-, 3-, and 5-year survivals. 
Fig 2. Survival after bronchoplastic surgery according to
TNM stage (n = 137; metastases of extrathoracic malignan-
cies and carcinoma in situ excluded). For 95% CIs, see text.
choplastic procedure, and respiratory and cardiovascu-
lar risk factors. Table VI summarizes their estimated
risk ratios (relative risks) of the Cox proportional haz-
ard model, CIs, and P values of the Wald test. The haz-
ard of patients with cardiovascular risk, for instance, is
estimated to be 104% (CI, 22%-239%) above the haz-
ard of patients without this risk. The hazard of patients
with respiratory risk is estimated to be 126% (CI, 39%-
268%) above the hazard of patients without such risk.
Besides the results of multivariable analysis, Table VI
gives the estimates and P values of univariable Cox
regression analyses, which confirm the results of mul-
tivariable analysis.
The data provide no evidence for an additional influ-
ence of age, sex, nodal status, histology, radicality of
resection, performance of angioplasty, and adjuvant ther-
apy. The data, however, do show a strong dependence
between age and respiratory and cardiovascular risk fac-
tors. Hence, the role of age as a risk factor may be cov-
ered and therefore concealed by these covariables.
Histology as a risk factor is assumed to be covered by
stronger factors as well. Moreover, the strong imbalance
of sample sizes over different histologic types makes it
difficult to distinguish between the histologic groups.
Discussion
Bronchial sleeve resection, first performed in the
1950s, has now evolved into a procedure of choice
for patients with compromised lung function to avoid
pneumonectomy with a curative or palliative intent.
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Fig 3.  Survival after bronchoplastic operation according to T
status (n = 137; metastases of extrathoracic malignancies and
carcinoma in situ excluded). For 95% CIs, see text.
Fig 4.  Survival according to type of bronchoplastic proce-
dure (n = 140; bronchotomies excluded). The 95% CIs are
given in brackets.
Fig 5.  Survival after bronchoplastic operation according to
preoperative respiratory risk (n = 144). Respiratory risk is
defined as FEV1 of less than 60% predicted and no respirato-
ry risk as FEV1 of 60% or greater. The 95% CIs are given in
brackets.
Fig 6. Survival after bronchoplastic operation according to
preoperative cardiovascular risk (n = 144). The 95% CIs are
given in brackets.
Sleeve resections may also be performed in patients
with good pulmonary function, achieving results as
good as those achieved with pneumonectomy.2,8,10
Many studies deal with univariate analyses of sleeve
resections in malignant and nonmalignant disease;
multivariable analyses were only applied in a few
studies.4,5
We performed a multivariable analysis to determine
putative prognostic factors of survival in a consecutive
series of sleeve resections, including carinal resec-
tions, as did Watanabe and colleagues.11 Like other
series in the literature, this number is not very large,
and therefore conclusions derived from a multivariable
model must be approached with caution. From 9 inves-
tigated risk factors, 4 independent factors were entered
into the analysis: TNM stage, type of surgical proce-
dure (ie, sleeve lobectomy, sleeve bilobectomy, and
sleeve pneumonectomy), and cardiovascular and respi-
ratory risks. From a statistical point of view, this result
does not mean that other factors have no influence;
they may be concealed by stronger factors. It must also
be taken into account that coding of the variables as
done by statisticians may influence the outcome. In
contrast to the long-term results of Van Schil and col-
league’s multivariate analysis4 with a minimum fol-
low-up of 5 years for surviving patients, our results are
based on a median follow-up period of 27 months for
surviving patients and a median survival of 7.9 months
for those who died. Thus, the number of patients at risk
is small at the 3-year follow-up; we did not generally
mention 5-year survivals. These small numbers might
also be the reason that survival of patients with N2 dis-
ease tends to be worse but does not achieve statistical
significance (3-year survival of 36% in N2 versus 63%
in N0). In those series that were followed up for a
longer period, however, nodal status is an important
prognostic factor.3,4 Our results correspond to the
series of Rendina and colleagues,12 who reported a 2-
year survival of 72% for lung cancer (about 65% in our
series) and favorable results in patients with benign
lesions, with the latter being alive 8 months to 3 years
after the operation. With the exception of 1 patient
who died of cerebral aneurysm, all our patients with
carcinoid tumors are alive.
In contrast to Van Schil and colleagues,4 we includ-
ed patients with incomplete sleeve resections, so-
called wedge resections described by Khargi and col-
leagues,13 and sleeve pneumonectomies to
summarize our total experience with bronchoplastic
procedures. Survival of total and partial bronchial
resections of lobes did not significantly differ,
although wedge resections tended to do better. The
decision to perform a partial or total sleeve resection
depended on the extent of bronchial infiltration by
the tumor or lymph nodes but was also influenced by
the decision of the individual surgeon. It must be
considered that this 2-center study comprises the
experience of a total of 8 main surgeons. The 30-day
mortality of 5.4% for lobar sleeve resections lies
within the range given in the literature.
In T4 tumors with carinal or tracheal invasion, how-
ever, 5-year survival may be as high as 20% but is sig-
nificantly worsened by N2 disease.14 Therefore, most
authors do not advocate resection in these cases.
However, we accept bronchoplasties with palliative
intent in cases with N2 disease or distant metastases
(eg, single brain lesions, which are amenable to surgi-
cal resection). Because the 1-year survival is as high as
25% for sleeve pneumonectomies in our series, we
strongly recommend that the indication for this type of
operation be established with great caution, consider-
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Table IV.  Mortality within 3 months after 
bronchoplastic operation
No.
Cause of death <1 mo
Cardiac failure-myocardial infarction 3
Pulmonary embolism 2





Cause of death <3 mo
Anastomotic dehiscence 3
Septic multiorgan failure caused by pneumonia 2
Respiratory failure 1
















ing the patient’s general condition and cardiorespirato-
ry risk factors. Because some long-term survivors have
been reported in literature,5,11 operation may be con-
sidered in the individual case despite the poor progno-
sis. Our series of 8 sleeve pneumonectomies included a
midterm survivor who was alive at 6.7 months after the
operation.
Because comorbidity has significant influence on
survival, patients chosen to undergo bronchoplastic
operations should be selected with caution. This con-
curs with the conclusions of Tedder and colleagues9 on
the basis of a review of 1915 patients with bron-
choplastic resections. Especially patients with cardio-
vascular risk factors, as well as those with impaired
pulmonary function, require a careful preoperative
evaluation. In these patients mediastinoscopy is strong-
ly indicated to exclude those with mediastinal disease.
We thank Gerhard Dekan, Department of Pathology,
University of Vienna, for cooperation.
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Discussion
Dr Thomas R. J. Todd (Toronto, Ontario, Canada). It is a
privilege to be asked to be the formal discussant for this not
small series of bronchoplastic procedures. My comments are
made on my review of the abstract, because Dr End’s unfor-
tunate inability to attend this meeting precluded my review-
ing the manuscript. I believe my comments are germane
nonetheless.
The first issue, of course, is survival. Two articles have
appeared within the last couple of years concerning the sur-
vival of patients with bronchogenic carcinoma after sleeve
resections. I want to draw your attention to the fact that sur-
vival is related to nodal status, which is not surprising at all.
Yet in the authors’ article today, survival did not appear to be
related to nodal status, and I would like you to comment as to
why you think that might be the case. Your first slide did say
that there were some 31 patients with N2 disease. Therefore,
I am surprised that survival was not related to N2 disease.
I think the bigger issue in this article is the mortality, which
you reported as 8%. However, your abstract also says that 4
deaths occurred beyond the 30-day limit as a result of anas-
tomotic problems. If I add those in, I get a mortality of 11%
and not 8%. However, even 8% is still high. Indeed, the high-
est mortality, 5%, is the one from my own center reported in
1979 by Dr Weisel. Why was the mortality in your series so
high? Weisel’s article pointed out that there were several
ways that we could stratify the type of patients coming to
operation. Indeed, it was 5% for those patients in whom the
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Table VI.  Results of multivariable and univariable analyses for survival in 144 bronchoplastic procedures
Multivariable analysis Univariable analysis
Risk factor Hazard risk 95% CI* P value Hazard risk P value
TNM stage 1.23 1.02–1.48 .0307 1.07 .0003
Surgical procedure 1.16 1.05–1.29 .0033 1.16 .0037
Cardiovascular risk 2.04 1.22–3.39 .0062 1.75 .0258
Respiratory risk 2.26 1.39–3.68 .0010 2.11 .0025
*CI, Confidence interval.
sleeve lobectomy was undertaken because the surgeon
believed it was the best operation for that patient. However, in
a separate group of patients in that article, in whom sleeve
lobectomy was done as a compromise procedure because of
concern that the patient would not tolerate a pneumonectomy
even though a pneumonectomy was thought to be indicated,
the mortality was actually 22%.
As I look through your article, I note that 21 patients had
an angioplasty, 31 patients had N2 disease, and 5 patients had
chest wall resections. Therefore, I have to wonder whether the
mortalities were related to compromised cardiopulmonary
function or to the presence of N2 disease. With N2 disease, of
course, you may be devascularizing a portion of the bronchus
as you do your complete nodal dissection. Therefore, my
question for you is simply this: How many of those 16 deaths
were in the group of patients who had compromised car-
diopulmonary function or who had N2 disease?
Dr Wolner. I apologize that you did not get the manuscript.
The overall mortality of the whole group, including this
fatal second operation, was 8%. Of the 8 patients in the sleeve
lobectomy group, 2 underwent pulmonary embolism and 1
underwent myocardial infarction. Perhaps a larger series will
then bring other results, but what is true is this 5.8% mortali-
ty among patients with the sleeve lobectomy. I think that we
had with this 60% cardiovascular risk and 60% respiratory
risk a group of patients with a higher risk generally in pul-
monary resection, and this could be my explanation.
Also surprising for us was the fact that these patients with
N2 disease were not so very different from the patients with
N0 or N1 disease. Perhaps this has something to do with the
low number of these patients after 5 years. It has also some-
thing to do, I hope, with the extended lymph node dissection
and all of the radiotherapy and chemotherapy after the opera-
tion. That would be my explanation for this unexpected result
of our multivariate and univariate analysis.
Dr Todd. Do you know what the mortality was within the
group of 21 patients who had angioplasty as well as sleeve
resection?
Dr Wolner. No. However, in the long-term survival, angio-
plasty has no influence. Therefore, I must speculate that there
was no difference.
Dr Steven J. Mentzer (Boston, Mass). Did you have any
data on local recurrence, that is, on the pattern of failure? In
addition, the abstract mentions dehiscence after 30 days. This
seems like a long time after the initial reconstruction. What
were the causes of the dehiscence?
Dr Wolner. No, we have no dehiscence.
Dr Mentzer. Did you have any local recurrences?
Dr Wolner. Yes. Of the 50 patients who died, 60% died of
local or distant disease, and 40% died of different reasons.
Dr Douglas E. Wood (Seattle, Wash). I agree with Dr
Todd’s points about the relationship to nodal disease and
angioplastic procedures, which is contradictory to several
other articles regarding sleeve resections. However, I am
going to restrict my questions and comments to the carinal
pneumonectomies. This is clearly a very difficult group of
patients, and in very experienced hands they have a mortality
of approximately 15%, ranging up to 30% at best. In your
series I believe it was 50%, which I think gives us all just
about when to consider carinal pneumonectomy as an extend-
ed resection for NSCLC.
I want to go back to your point that 2 of your patients
required cardiopulmonary bypass. My adage that I give to the
residents is that in bronchoplastic procedures, including cari-
nal pneumonectomies, most of them are straightforward
enough that they do not require cardiopulmonary bypass, and
if they are enormously complicated, then cardiopulmonary
bypass is contraindicated. Therefore, we always come up
with some routine to manage to do the operations off-pump.
Did the 2 patients who had cardiopulmonary bypass undergo
carinal resections, and did they die in the postoperative peri-
od? I think that would be useful to know and potentially pro-
vide experience in favor of or against cardiopulmonary
bypass to support of bronchoplastic procedures.
Dr Wolner. First, let me start my answer by saying that we
are a department of cardiothoracic surgery and we do about
1300 heart operations per year besides these 700 different
general thoracic procedures. Therefore, in general I am sure
we are more liberal in using cardiopulmonary bypass if it
seems to be necessary. However, these patients are not among
those who died. One patient who died had an infiltration in
the aorta and a piece of the aorta was replaced. The other
patients were in severe trouble on admission because of
bleeding at the junction of the superior vena cava and the
innominate vein. Fortunately, this situation is rare in cardiac
operations, but it is very difficult to treat. This was the second
case with the heart-lung machine. Therefore, cardiopul-
monary bypass was used in 2 of these 3 patients because of
catastrophic vascular problems during the operation. 
Dr Wood. Neither one died?
Dr Wolner. No.
Dr David J. Sugarbaker (Boston, Mass). I have two com-
ments. At the Brigham Hospital, any patient who would be
considered for carinal pneumonectomy would undergo a
mediastinoscopy, and if N2 disease was determined to be pre-
sent, that patient would be ruled out for routine carinal pneu-
monectomy outside of some specific protocol or clinical trial.
My first question to you is this: Because in your particular
abstract N2 disease was indeed a poor predictor of survival,
what is the role of mediastinoscopy for any patient whom one
might consider for carinal pneumonectomy? Second, what is
your technique in terms of using a parathymic-pericardial fat
pad or other buttress of your bronchoplastic suture line?
Dr Wolner. With regard to the first question, usually we try
to obtain complete staging of the disease in all of our patients.
As you know, in the last year there has been some change in
staging with the computed tomographic scan, but I cannot tell
you what the percentage is or how many mediastinoscopies
were done. In general, when we have a suspicion that there is
N2 disease on the basis of the computed tomographic scan,
the x-ray film, and so on, a mediastinoscopy or a thora-
coscopy will be performed.
To answer the second question, we use polydioxanone
sutures (PDS-40; Ethicon, Inc, Somerville, NJ) and in some
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cases, but not all, we use intercostal flaps or pericardial flaps
and fibrin glue.
Dr Douglas J. Mathisen (Boston, Mass). Could you please
describe the technique you use to do bronchoplasty? Is it
open, interrupted, or running?
Second, a number of your patients had bilobectomies and
bronchoplastic procedures. In that group did you notice any
size discrepancy, and if you did find size discrepancy, could
you share with us how you dealt with that problem?
Dr Wolner. This is from two hospitals, and the majority of
the anastomoses were done with a polydioxanone running
suture, but I cannot tell you how many. There were some with
a single-stitch technique. If there is a size discrepancy, we use
the usual technique with a longitudinal incision, which I use
in vascular operations, to bring together the two stumps.
Dr L. Penfield Faber (Chicago, Ill). Quoting from the
abstract, “The presence of cardiac risk factors, chronic
obstructive disease, N2 disease, R1 resection, performance of
sleeve pneumonectomy with a 50% mortality had an adverse
influence on survival.” With these points in mind, I would
appreciate your telling us what your absolute contraindica-
tions are for bronchoplastic procedures.
Dr Wolner. That is a very good question. I would say my
personal feeling is that if you have a patient who is under 70
years with a bronchial carcinoma and no distant metastases
who seems, from your staging, to be a candidate for resec-
tion, then I am more in favor of resection. Also, there was this
discussion before of brain metastasis and N1 disease and
whether we should resect. My personal attitude for many
years in such cases is to be more on the side of the operation.
It is clear that if you have distant metastases, pleural involve-
ment, or diseased lymph nodes outside of the mediastinum
(contralateral), then you have contraindications. Those are
the typical indications for chemotherapy and radiotherapy.
Dr Todd. I will just make one other technical comment.
Somebody did bring up the role of mediastinoscopy before
doing sleeve pneumonectomy. Coming from a place where
mediastinoscopy is really quite routine, the one lesson we have
learned is that if we are contemplating from the endobronchial
appearance that we are going to need to do a sleeve pneu-
monectomy, that is the one time when I really do want to do the
mediastinoscopy at the same time as the procedure. If you do it
before the procedure and then go back, it is a little harder to pull
that trachea down to get your anastomosis done without tension.
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